Encompass Health (EHC) Set to Announce Earnings on Wednesday

Encompass Health (NYSE:EHC) is set to post its quarterly earnings results after the market closes on Wednesday, April 24th. Analysts expect Encompass Health to post earnings of $0.93 per share for the quarter. Encompass Health has set its FY24 guidance at $3.77-$4.06 EPS and its FY 2024 guidance at 3.770-4.060 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, February 7th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.12. Encompass Health had a return on equity of 17.69% and a net margin of 7.33%. The firm had revenue of $1.25 billion for the quarter, compared to analyst estimates of $1.24 billion. On average, analysts expect Encompass Health to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Encompass Health Trading Up 1.4 %

NYSE:EHC opened at $80.29 on Tuesday. Encompass Health has a 1-year low of $57.55 and a 1-year high of $83.73. The business’s 50-day moving average price is $77.52 and its two-hundred day moving average price is $70.47. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $8.04 billion, a price-to-earnings ratio of 23.14, a PEG ratio of 1.47 and a beta of 0.94.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend was Thursday, March 28th. Encompass Health’s payout ratio is 17.29%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on EHC shares. Mizuho raised their price target on Encompass Health from $77.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. Truist Financial raised their price target on Encompass Health from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Friday, February 9th. Stephens reaffirmed an “overweight” rating and set a $85.00 price target on shares of Encompass Health in a research report on Tuesday, January 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $83.00 price target on shares of Encompass Health in a research report on Friday, February 9th. Finally, William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Wednesday, February 7th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $83.22.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.